SBFM Stock Analysis: Buy, Sell, or Hold?
SBFM - Sunshine Biopharma Inc.
$1.95
-0.14 (-6.70%)
▼
5d:
-10.55%
30d:
-8.88%
90d:
+95.31%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When SBFM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SBFM is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SBFM is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.92
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$2.44
20.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SBFM is currently trading at $1.95, which is considered oversold relative to its 30-day fair value range of $2.04 to $2.28. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.8) compared to its historical average (14.0). Remarkably, the market is currently pricing in an annual earnings decline of 11.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SBFM is showing sideways momentum. Immediate support is located at $0.25, while resistance sits at $3.05. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $56.00 (+2771.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SBFM is showing sideways momentum. Immediate support is located at $0.25, while resistance sits at $3.05. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $56.00 (+2771.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.04 -
$2.28
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading 2771.8% below Wall St target ($56.00)
- WARNING: Recommendation downgraded due to -10.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.04 -
$2.28
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.25
Resistance Level
$3.05
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.75
Wall Street Target
$56.00
(+2771.8%)
Revenue Growth (YoY)
-9.1%
Profit Margin
-17.0%
Valuation Discount vs History
-11.4% cheaper
PE vs Historical
9.8 vs 14.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.4%
(market-implied from PE analysis)
1-Year Target
$1.76
(-10%)
2-Year Target
$1.58
(-19%)
3-Year Target
$1.42
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→14)
$2.04
(+5%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 14.0
Stabilization Target:
$2.80
(+43.6%)
PE Expansion Potential:
+43.6%
Share & Embed Analysis
Last updated: July 14, 2026 9:01 AM ET
Data refreshes hourly during market hours. Next update: 10:01 AM
Data refreshes hourly during market hours. Next update: 10:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SBFM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
